Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| ICS-H52Ha | Human | Human ICOS / CD278 (C136S, C137S) Protein, His Tag, active dimer (MALS verified) |
|
|
|
| ICS-R52H9 | Rat | Rat ICOS / CD278 (C137S, C138S) Protein, His Tag |  |
|
|
| ICS-M5259 | Mouse | Mouse ICOS / CD278 (C137S, C138S) Protein, Fc Tag |  |
|
|
| ICS-M52H8 | Mouse | Mouse ICOS / CD278 (C137S, C138S) Protein, His Tag |  |
|
|
| ICS-H5258 | Human | Human ICOS / CD278 Protein, Fc Tag |  |
|
|
| ICS-H82E5 | Human | Biotinylated Human ICOS / CD278 (C136S, C137S) Protein, His,Avitag™ (recommended for biopanning) |  |
|
|
Immobilized Rat ICOS / CD278 (C137S, C138S), His Tag (Cat. No. ICS-R52H9) at 5 μg/mL (100 μL/well) can bind Mouse B7-H2, Fc Tag (Cat. No. B72-M5258) with a linear range of 2-39 ng/mL (QC tested).
The purity of Human ICOS Protein, His Tag (Cat. No. ICS-H52Ha) is more than 90% and the molecular weight of this protein is around 52-62 kDa verified by SEC-MALS.
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Izuralimab | XmAb-23104; XmAb-104 | Phase 2 Clinical | Xencor Inc | Sarcoma; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma; Endometrial Neoplasms; Colorectal Neoplasms; Breast Neoplasms; Nasopharyngeal Carcinoma; Solid tumours; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms | Details |
| Feladilimab | GSK-609; GSK-3359609 | Phase 2 Clinical | Glaxosmithkline Plc | Head and Neck Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Multiple Myeloma | Details |
| Alomfilimab | KY-1044 | Phase 2 Clinical | Kymab Ltd | Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Esophageal Neoplasms; Triple Negative Breast Neoplasms; Neoplasms; Pancreatic Neoplasms; Melanoma; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis | Details |
| Acazicolcept | ALPN-101 | Phase 2 Clinical | Alpine Immune Sciences Inc | Graft vs Host Disease; Autoimmune Diseases; Lupus Erythematosus, Systemic; Lymphoproliferative Disorders; Inflammation | Details |
| Vopratelimab | JTX-2011 | Phase 2 Clinical | Jounce Therapeutics Inc | Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| MEDI-570 | Phase 1 Clinical | Japan Tobacco (Hong Kong) Ltd | Lymphoma, Follicular; Lupus Erythematosus, Systemic; Lymphoma, T-Cell, Cutaneous; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Mycosis Fungoides | Details | |
| Anti-ICOS (Bristol Myers Squibb) | BMS-986226 | Phase 1 Clinical | Bristol-Myers Squibb Company | Neoplasms | Details |
This web search service is supported by Google Inc.
A-Z
